NAIROBI, Kenya—Jan 26, 2026—Cervical cancer does not announce itself loudly. In its early stages, it is often silent — no pain, no bleeding, no obvious warning signs. Many women live with the disease for months, even years, unaware that cancer is quietly advancing in their bodies.
By the time symptoms such as abnormal bleeding, unusual discharge, persistent back pain or bowel changes appear, the disease is often already advanced and far more dangerous. This silence is cervical cancer’s greatest risk — and one of Kenya’s most urgent public health challenges.
Today, cervical cancer kills about 10 Kenyan women every day. It is the leading cause of cancer-related deaths among women and the second most common cancer after breast cancer. Without decisive intervention, projections from the 2022 Kenya Demographic and Health Survey (KDHS) show daily deaths could more than double to 22 by 2040.
These are not abstract numbers. They represent mothers, daughters, professionals and caregivers lost to a disease that is largely preventable and highly treatable when detected early.
Late diagnosis remains the single biggest driver of poor outcomes. Nearly two-thirds of cervical cancer cases in Kenya are detected only after the disease has progressed. At that stage, treatment options are limited, costly and far less effective. Survival rates are sobering: only about 57 per cent of patients survive one year after diagnosis, dropping to 45 per cent after two years. Just one-third of patients receive the full course of treatment; many receive only palliative care.
Low screening rates lie at the heart of this crisis. According to KDHS data, only 16.8 per cent of Kenyan women have ever been screened for cervical cancer. For years, screening coverage among HIV-negative women fluctuated wildly, at times falling below one per cent. HIV-positive women — who face higher risk — fare even worse. As recently as 2018, only a quarter of health facilities nationwide offered screening services.
Why do so many women miss this life-saving intervention? The barriers are deeply human. Fear of pain, anxiety about a positive result, discomfort with male providers, past traumatic experiences, and lack of time — especially for working women and caregivers — all play a role. Cost is another major obstacle. A Pap smear can range from Sh1,000 in public facilities to Sh10,000 in private hospitals, putting screening out of reach for families surviving on a few hundred shillings a day.
This is why cervical cancer must be understood not only as a medical issue, but as a systemic risk. Health risks left unmanaged become financial, social and productivity risks. When women fall ill or die prematurely, households lose income, children lose caregivers, and employers lose skilled talent.
There is progress to build on. Since the introduction of HPV vaccination in 2019, first-dose coverage rose from 24 per cent in 2022 to over 60 per cent by the end of 2024. The shift to a single-dose regimen in late 2025 could further accelerate uptake. Yet Kenya still falls short of the World Health Organisation’s 90-70-90 elimination targets on vaccination, screening and treatment.
Closing this gap requires more than policy statements. It demands coordinated risk awareness, sustainable financing, workplace support and community-level action. Employers can normalise screening through workplace programmes, insurers can reduce out-of-pocket costs, and healthcare systems must ensure affordable services, respectful care and reliable follow-up.
January, Cervical Cancer Awareness Month, should be more than a moment of reflection. Cervical cancer may be silent in its early stages, but our response must not be. Early screening, vaccination and informed risk management can save thousands of Kenyan lives.
[The writer Dr. Crystal Vulavu is the Head of Corporate Wellness at Minet Kenya].
